Skip to main content
KTTA
NASDAQ Life Sciences

Pasithea Therapeutics Appoints Experienced CMO, Grants Substantial Equity Options to Executives and Directors

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.847
Mkt Cap
$21.114M
52W Low
$0.281
52W High
$3.79
52W Position info
201% above low
Off High info
78% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

KTTA has more than doubled off its 52-week low of $0.281.

Summary

Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer, a strategic move for its clinical-stage pipeline, accompanied by significant stock option grants to executives and directors.


Key Events · Executive and Board Changes · KTTA

  • Chief Medical Officer Appointed

    Dr. Kartik Krishnan, M.D., Ph.D., was appointed Chief Medical Officer, effective May 1, 2026. He will oversee clinical development and medical strategy for PAS-004, particularly for neurofibromatosis type 1 (NF1).

  • Extensive Industry Experience

    Dr. Krishnan has over 20 years of experience, including roles as CEO at OncoNano Medicines and CMO at Arcus Biosciences. His prior work at Genentech on the FDA-approved MEK inhibitor cobimetinib is directly relevant to Pasithea's lead candidate.

  • Executive Compensation Details

    Dr. Krishnan's employment agreement includes an initial annual base salary of $500,000 and eligibility for an annual discretionary bonus of up to 40% of his base salary.

  • Significant Stock Option Grants

    The Board approved stock option awards for 5,865,170 shares of common stock to executive officers (including Dr. Krishnan, CEO Tiago Reis Marques, and Daniel Schneiderman), certain employees, and non-employee directors. The exercise price for all options is $0.841 per share, the closing price on May 1, 2026.


Analysis · KTTA · Life Sciences

Pasithea Therapeutics, a clinical-stage biotechnology company, has appointed Dr. Kartik Krishnan as its Chief Medical Officer. Dr. Krishnan brings over 20 years of experience in clinical development, including work on an FDA-approved MEK inhibitor, which is highly relevant to Pasithea's lead candidate, PAS-004, for neurofibromatosis type 1 (NF1). This appointment is a significant positive for the company's clinical strategy and its ability to advance PAS-004. In connection with this, the company granted substantial stock options to Dr. Krishnan, the CEO, CFO, other employees, and non-employee directors. While these grants represent significant potential future dilution, they are a necessary component of attracting and retaining key talent critical for a clinical-stage biotech's success.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KTTA was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.1M. The 52-week trading range was $0.28 to $3.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 17, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4343
Real-time Price: $0.4343 info
Change: $0 (0%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.4343 info
Change: -$0.0447 (-9%) info
Market Cap: $15.962M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.4343 info
Change: -$0.0757 (-15%) info
Market Cap: $15.962M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.4343 info
Change: +$0.0752 (+21%) info
Market Cap: $15.962M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.4343 info
Change: -$0.1157 (-21%) info
Market Cap: $15.962M info